CZ Biomed Corp

About Company

CZ BioMed Corp is a privately held Biotechnology company focuses on discovery, development, and commercialization of a new class of potent genetically engineered common cold virus (RVLYSIS) that selectively kills tumor cells, but not normal cells. With this medical breakthrough potentially will help millions of people worldwide in the fight against cancer.
Founded in 2009 and Incorporate in 2010 as a Nevada Corp and its corporate headquarters in Tampa, Florida.

Our Mission

Our mission are rooted in the knowledge of our invention and the products we provide affect the quality of patients' lives. Since everything we do, no matter how small, impacts the end product, we demand the highest ethical and quality standards, both from ourselves and others.

These mission drive us to achieve excellence and build quality in absolutely everything we do which lead to the discovery of a new class of high-tech biological products for the treatment of a wide variety of human cancers.

Management

Calvin Cao: Chairman/CEO/President

Mr. Cao's is the founder of CZ BioMed Corp. As an inventor, innovator and Bio-Entrepreneur, his strategy and commitment to make CZ Biomed the dominant global company on the discovery and development of a new class of high-tech biological products for the treatment of a wide variety of human cancers.

In 2008, As a chairman and co-founder of Stem Cell Therapy International Corp. He engineered the recent merger of Stem Cell Therapy International and Histostem of South Korea. Histostem, one of the largest fully accredited cord blood banks in the world, with more than 80,000 cord blood units for use in research and treatments. The successful merger has formed one of the first fully merged Pacific Rim stem cell companies and cord blood repositories with a U.S. entity Amstem Corp.

John Zhang, MD., Ph.D: Chief of Scientist/Vice President

Dr. Zhang got his M.D. and Ph.D. degrees in China . He has been working on Virology and Tumor biology for more than ten years. He has a broad background in these fields and expertise in key research areas for this application. He laid the groundwork for the oncolytic virus project by developing effective system to kill broad types of tumors. As a result of these previous experiences, he has more than 50 peer-reviewed publications. In summary, he has a demonstrated record of successful and productive research projects in an area of high relevance for oncolytic virus field, and his expertise and experience have prepared us to lead the ongoing project.

Lixian Jiang, Ph.D: Chief Operating Officer/ Vice President

Dr. Lixian (John) Jiang, is a senior Attorney from China and a Patent Agent in the US . He specializes in intellectual property law, China tax law and corporate law. He has worked in a number top specialty law firms. In addition, Dr Jiang is a stem cell scientist. He graduated from University of South Florida Medical School with a PhD degree. He has published around 60 original medical articles and abstracts.

Dr. Ronald E. Wheeler, M.D. : Medical Director / Scientific and Medical Advisory Board

A practicing Urologist for more than 20 years, Dr. Wheeler has focused on male related health issues including impotency and Prostate Diseases associated with BPH, Prostatitis, and Prostate Cancer. He has been a member of the American Urologic Association since 1985 and is a member of the National Institute of Health(NIH) Prostatitis Collaborative.

He is currently Medical Director of the Diagnostic Center for Disease located in Sarasota, FL and of the Prostate Cancer Prevention Foundation.

Other professional highlights include:

Owner of two patents on Prostatitis Detection and Resolution

Principal investigator in a Neo-Adjuvant study for Organ Confined Prostate Cancer, by Schering Pharmaceuticals

A member of the esteemed Royal College of Alternative Medicine (RCAM).

Certified in High Intensity Focused Ultrasound (HIFU), a novel prostate cancer treatment currently involved in Phase 3 trials at the FDA. Currently treating patients in Canada, Dominican Republic, Mexico, and the Bahamas.

Author of numerous prostate related articles.

Member of Advisory boards for several health realated corporations and foundations including: Sanofi-Aventis Ocoology, Urology Times, PAACT, Prostate Awareness Foundation, Glaxo Smith Kline, Abbott, and Radiation Centers of America.

Frequent Speaker on various radio stations and, meetings, and related symposiums.

Dr. William Brown Ph.D., J.D., MBA - General and Intellectual Property Lawyer

J.D. (magna cum laude), New York Law School (1998).

M.B.A. (management major), Fairleigh Dickinson University (1997).

Ph.D. (molecular biology/biochemistry), University of Southampton (1991).

B.Sc. (summa cum laude; biochemistry/chemistry), University of Southampton (1988).

CURRENT EMPLOYMENT:

Director, Intellectual Property, Sanofi Pasteur, VaxDesign Campus, Orlando, FL. Responsible for IP strategy, management of outside counsel, patent drafting and prosecution (2005-present; in 2010, VaxDesign Corp. was acquired by and is now a wholly owned subsidiary of Sanofi Pasteur).

Advisor, Intellectual Property, NB Capital / Nordic Biotech, Copenhagen, Denmark. Responsible for IP due diligence, validity, infringement, patentability, and freedom-to-operate issues (2005-present).

Click to view Curriculum Vitae

Dr. Kenneth Forster Ph.D. - Medical Advisory Board Member

Current Position:

Associate Member

Medical Physicist

Department of Radiation Oncology

Moffitt Cancer Center and Research Institute

Click to view Curriculum Vitae

Business Model

We Model our business after the case study by Harvard Business Review in March 2008 issue (Harvard Business Review Article) in this model Choruspharma was a virtual drug development Biotech Company setup by Eli Lilly as an experimental in 2002.

We believed we could transform the traditional biologics drug development process through a lean approach to generating clinical proof of concept data, and a 100% outsourcing model.

As a privately held Biotechnology company our goal is to take a biologics-drug to a proof of concept (POC) in less than two years, after which it will be licensed out.

We now have 8 products candidate and ready to be licensed out: LURVLYSIS for the treatment of Lung cancer, BRVLYSIS for the treatment of Breast cancer, PRORVLYSIS for the treatment of Prostate cancer, CORVLYSIS for the treatment of Colon cancer, CERVLYSIS for the treatment of Cervical cancer, MERVLYSIS for the treatment of Melanoma cancer, HERVLYSIS for the treatment of Liver cancer, OVARVLYSIS for the treatment of Ovarian cancer.

The goal is to licensed all 8 products to 8 different Pharmaceutical companies and collect upfront payment, milestone payment and royalty payment from each Pharmaceutical company.

With over $100 billion worth of Revenue on Patent Expiration of the Top 12 Pharmaceuticals companies by 2012. We believed that we will find more than one of these Pharmaceutical company to partner with to develop our new class of high-tech biological products for the treatment of a wide variety of human cancers.

Investors

Global Capital Corp.

Stemcell Lab Corp.

GIG Pharm Inc.

Golden Sources Investment Group Inc.